Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

First Contract Win for Instem Clinical

2 Jul 2013 07:00

RNS Number : 3502I
Instem plc
02 July 2013
 

2 July 2013

Embargoed for 07:00

Instem plc

("Instem", the "Company" or the "Group")

First Contract Win for Instem Clinical

Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, is pleased to announce its first contract win for its newly acquired ALPHADAS software. The contract consists of a high six-figure GBP perpetual licence plus implementation services, with ongoing annual support and maintenance.

ALPHADAS,the market leading, e-source data capture ("EDC") system and site automation software suite for early phase clinical studies, has been selected by a UK-based global leader in the provision of specialisedclinical services. ALPHADAS is now offered by Instem Clinical, formerly Logos Technologies, which was acquired by Instem in May 2013.

Replacing a more traditional 'form based' EDC system, ALPHADAS was selected for its ability to deliver an immediate and significant return on investment within the client's highly complex studies. ALPHADAS sources data direct from instrumentation, removes errors at source, tracks samples from collection to dispatch and enables critical real time data review. Further efficiencies are also delivered by ALPHADAS through its ability to track study subjects throughout the recruitment process, staff resourcing and site management and the provision of a fully visible audit trail.

Phil Reason, CEO of Instem plc, commented, "We are delighted to be able to announce a significant contract win for Instem Clinical, so quickly after it was established following the acquisition of Logos in May this year. A leader in their field and experiencing significant growth, the new client is currently working with some of the world's foremost pharmaceutical and research companies. This is a clear demonstration of the quality of the ALPHADAS software and the opportunity to expand Instem's market to early clinical studies."

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

About Instem plc

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports its clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com or its investor centre http://investors.instem.com/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGUAWMUPWPGG
Date   Source Headline
21st Nov 20237:00 amRNSCancellation of admission to trading
21st Nov 20237:00 amRNSCancellation - Instem Plc
20th Nov 202312:33 pmRNSScheme becomes Effective
20th Nov 20237:30 amRNSSuspension - Instem PLC
17th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
16th Nov 20233:23 pmRNSIssuance of Shares following Court Sanction
16th Nov 20232:30 pmRNSCourt Sanction of the Scheme
16th Nov 202310:02 amRNSForm 8.5 (EPT/RI)
15th Nov 20231:40 pmPRNForm 8.3 - Instem Plc
15th Nov 202310:16 amRNSForm 8.5 (EPT/RI)
14th Nov 20235:30 pmRNSInstem
14th Nov 20233:01 pmGNWForm 8.3 - Instem plc
14th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
14th Nov 202311:08 amRNSForm 8.5 (EPT/RI)
14th Nov 202310:19 amRNSForm 8.3 - Instem Plc
13th Nov 20232:30 pmPRNForm 8.3 - Instem Plc
13th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
13th Nov 202310:03 amRNSForm 8.5 (EPT/RI) - Instem plc
13th Nov 202310:00 amRNSForm 8.3 - Instem Plc
10th Nov 20233:14 pmPRNForm 8.3 - Instem Plc
10th Nov 202312:03 pmGNWForm 8.3 - Instem plc
10th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
10th Nov 202310:24 amRNSForm 8.3 - Instem Plc
9th Nov 20233:27 pmRNSForm 8.3 - Instem PLC
9th Nov 20231:42 pmPRNForm 8.3 - Instem Plc
9th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
9th Nov 202310:17 amRNSForm 8.3 - Instem Plc
8th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
7th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
7th Nov 202311:40 amRNSForm 8.5 (EPT/RI)
7th Nov 20237:00 amRNSSatisfaction of Conditions
6th Nov 20234:28 pmRNSForm 8.3 - INSTEM PLC (replaces RNS 5325S &5364S)
6th Nov 20234:00 pmRNSForm 8.3 - INSTEM PLC (cancel & replace RNS5325)
6th Nov 20233:05 pmRNSForm 8.3 - INSTEM PLC
6th Nov 20233:00 pmRNSForm 8.3 - Instem PLC
6th Nov 20232:10 pmGNWForm 8.3 - Instem Plc
6th Nov 20231:30 pmPRNForm 8.3 - Instem Plc
6th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
3rd Nov 20235:56 pmRNSHolding(s) in Company
3rd Nov 20231:52 pmPRNForm 8.3 - Instem Plc
3rd Nov 20231:39 pmRNSHolding(s) in Company
3rd Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
3rd Nov 20239:49 amRNSForm 8.5 (EPT/RI)
3rd Nov 20237:05 amRNSForm 8.3 - Instem plc
2nd Nov 20232:25 pmRNSResults of Court Meeting and General Meeting
31st Oct 20239:39 amRNSForm 8.5 (EPT/RI)
30th Oct 202310:09 amRNSForm 8.5 (EPT/RI)
30th Oct 20237:00 amRNSOffer Update
27th Oct 20233:00 pmBUSForm 8.3 - INS LN
27th Oct 20231:09 pmGNWForm 8.3 - Instem Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.